Quick Heal Technologies Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 17 Jul 2026 | IT - Software | Market Cap: ₹830 Cr
The enterprise (B2B) segment is expected to grow steadily, with current new product segments contributing 13%-15% to enterprise revenue and a strong pipeline indicating future growth. Quick Heal acknowledges current challenges including softer consumer market and deferred enterprise deals impacting near-term revenue and profitability (Page 4).
From Quick Heal Technologies Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹143
Market Cap
₹830 Cr
How does Quick Heal Technologies Ltd rank in IT - Software?
Compare Quick Heal Technologies Ltd against every IT - Software company this quarter on revenue, margins and earnings-call signals.
Quick Heal Technologies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹49 Cr, net profit ₹-20 Cr.
Full financials →📊 Revenue & Sales Performance
- →The enterprise (B2B) segment is expected to grow steadily, with current new product segments contributing 13%-15% to enterprise revenue and a strong pipeline indicating future growth.
- →The company acknowledges a gestation period for enterprise cybersecurity business but remains confident in its foundational investments and future growth.
- →Recent large deal wins, particularly in data privacy with a tier one BFSI client, boost confidence in future sales growth.
- →The consumer (B2C) segment is currently facing softness and declining revenue but remains part of the overall revenue mix.
- →Management is focused on driving revenue recovery, managing expenses, and leveraging strategic expansions including international markets.
- →Ongoing investments in product innovation and expanding the partner ecosystem are expected to fuel sustainable value creation over time.
- →No specific quantitative guidance on next 3-5 years revenue, but management emphasizes patient growth and improving margins.
📈 Profitability & Margins
- →Quick Heal acknowledges current challenges including softer consumer market and deferred enterprise deals impacting near-term revenue and profitability (Page 4).
- →The enterprise pivot is critical for future growth; though current growth in enterprise revenue is modest (13-15%), management is confident about the strong foundation laid for growth (Pages 5-6).
- →Multiple large deals, especially in data privacy, have been won, indicating emerging growth in the enterprise segment (Page 9).
- →Management remains patient, expecting gradual margin expansion as enterprise revenues ramp up over the next few years (Page 6).
- →Commitment to innovation and ongoing investments in product development support a long-term growth trajectory (Pages 3-4).
- →No explicit three- or five-year earnings/EPS guidance provided, but management intends to improve revenue recovery and margins through strategic expansion and higher enterprise contribution (Pages 4-6).
- →Order book and pipeline visibility are improving, with plans to share more granularity in future quarters (Page 8).
🏗️ Capital Expenditure Plans
- →The transcript does not explicitly mention any current or future capital expenditure (capex) or strategic investments by Quick Heal Technologies Limited.
- →The company remains focused on continued investments in product development, particularly in building features for their data privacy product and enterprise platform.
- →Investment emphasis is on innovation and expanding product functionalities, including AI-driven threat detection and data privacy compliance tools.
- →The management is currently investing in strengthening the enterprise business and sales organization, which is considered critical for future growth.
- →There is also an ongoing active search for a new CEO, indicating strategic leadership planning.
- →No explicit monetary capex figures or strategic investment details are disclosed in the provided transcript.
💰 Fundraising & Capital Structure
📋 Order Book & Pipeline
- →Quick Heal disclosed an order book of Rs.24 crores as of the recent quarters.
- →There is also a deferred revenue of around Rs.16 crores, indicating revenue visibility.
- →The company has not provided specific pipeline numbers currently but acknowledged the importance of doing so for investor clarity.
- →Management is working on providing more granularity on order book conversion timelines and pipeline insights in upcoming quarters.
- →The pipeline is described as "healthy" and "improving" with good visibility.
- →Multiple proof of concepts (POCs) and proposals are ongoing, with expectations of closing more deals soon.
- →A significant recent win includes a large deal with a tier-one Indian BFSI client in the data privacy domain, boosting confidence.
- →Management is confident about future growth prospects based on the foundation laid and strong pipeline.
Key Metrics
Frequently Asked Questions
What were Quick Heal Technologies Ltd Q1 FY26 results?
The enterprise (B2B) segment is expected to grow steadily, with current new product segments contributing 13%-15% to enterprise revenue and a strong pipeline indicating future growth. Quick Heal acknowledges current challenges including softer consumer market and deferred enterprise deals impacting near-term revenue and profitability (Page 4).
What is Quick Heal Technologies Ltd share price analysis?
Quick Heal Technologies Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹830 Cr. Investors should review the full earnings analysis for detailed insights.
Is Quick Heal Technologies Ltd planning capital expenditure?
The transcript does not explicitly mention any current or future capital expenditure (capex) or strategic investments by Quick Heal Technologies Limited.
Keep Quick Heal Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.